Form 4 for VOR Vor Biopharma Inc.
Accepted 2023-02-08 00:00:00 ET · period of report 2023-02-06 · accession 0001209191-23-007794 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-02-08 | 2023-02-06 | VOR | ANG ROBERT | Pres, CEO, Dir | A - Grant | $0.00 | +128.8K | 713.3K | +22% | $0 |
| D | 2023-02-08 | 2023-02-06 | VOR | ANG ROBERT | Pres, CEO, Dir | A - Grant | $0.00 | +257.5K | 257.5K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-02-06 | A | A | 128,750 | $0.00 | 713,322 | D | — | — | (F1) Represents the number of shares underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest over four years in equal quarterly installments beginning February 6, 2023, subject to the Reporting Person's continued service as of each such date. |
| 2 | Derivative | Employee Stock Option (right to buy) | 2023-02-06 | A | A | 257,500 | $0.00 | 257,500 | D | $5.55 · — to 2033-02-05 | 257,500 Common Stock | (F2) The shares shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on February 6, 2023, in each case subject to the Reporting Person's continued service as of each such date. |